Soluble‐type hepatobiliary contrast agents for MR imaging

Haën, Christoph de; Gozzini, Luigia

doi:10.1002/jmri.1880030130

Cited by 51 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gadobenate dimeglumine (Gd-BOflAI is a octandentate chelate of gadolinium, which couples nonspecific distribution into the extracellular space, with specific hepatocyte uptake and biliary excretion. The Gd-BOPTA uptake by liver cells is thought to be mediated by an active membrane transport system and the uptake and metabolism of Gd-BOPTA has been related to liver cell function (1).…”

Section: Discussionmentioning

confidence: 99%

“…GADOBENATE DIMEGLUMINE (BOPTA) is a new octandentate chelate of gadolinium, which couples nonspecific extracellular distribution with specific hepatocyte uptake and biliary excretion ( 1). Preliminary in vitro studies have proved gadolinium-BOPTA to have a high biliary excretion rate (2).…”

mentioning

confidence: 99%

“…In liver cirrhosis there is a decreased liver cell function compared with non-cirrhotic liver parenchyma; therefore, it had been hypothesised that cirrhotic liver parenchyma would show reduced enhancement, relative to non-cirrhotic liver parenchyma, due to impairment of uptake and transport mechanism of Gd-BOFTA (1).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

Manfredi

Maresca

Baron

et al. 1998

Magnetic Resonance Imaging

View full text Add to dashboard Cite

To determine whether gadobenate dimeglumine (BOPTA) will adequately enhance cirrhotic liver parenchyma, and to document the enhancement patterns in cirrhosis, 14 cirrhotic and 20 non-cirrhotic patients were evaluated before and 60-120 minutes after gadolinium-BOPTA. Proof of liver cirrhosis was biopsy (6), surgical resection (3), and clinical follow-up (5). Enhancement effects were compared quantitatively by determining the liver signal-to-noise ratio (SNR) and signal enhancement in both populations. Qualitatively assessment of the liver enhancement was performed and classified as homogeneous or heterogeneous. Quantitative analysis: cirrhotic liver parenchyma presented a higher increase in SNR values, relative to non-cirrhotic liver parenchyma, on postcontrast images. Likewise the signal enhancement of cirrhotic liver parenchyma was superior to non-cirrhotic liver on T1-weighted SE images (P = .02) and in-phase GRE images (P < .001). There was no statistical difference on out-of-phase GRE images. Qualitative analysis: on T1-weighted SE postcontrast images, cirrhotic liver parenchyma showed a homogeneous enhancement in 7 patients and heterogeneous in 7. Whereas on GRE images, cirrhotic parenchyma showed heterogeneous enhancement in 9 patients and homogeneous in 5 patients. The heterogeneous enhancement was due to the presence of hypointense nodules in 7 patients and hyperintense nodules in 2 patients. In conclusion, our study has shown that the hepatobiliary contrast agent Gd-BOPTA is effective in the cirrhotic liver, demonstrating an increased liver enhancement compared with non-cirrhotic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

Manfredi

Maresca

Baron

et al. 1998

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…In humans, biliary excretion is only approximately 4% (6). In spite of its modest hepatocellular uptake, the relaxivity of Gd-BOPTA within hepatic tissue is high, which may be related to the high intracellular macromolecular binding of Gd-BOPTA (2). It therefore provides prolonged plateau-like enhancement of the liver (1).…”

Section: Discussionmentioning

confidence: 95%

“…Their overall aim is to increase soft-tissue contrast between liver and focal liver masses potentially allowing improvement in lesion detection at MR imaging. Gadobenate-dimeglumine (Gd-BOPTA) is a paramagentic contrast agent with partial biliary excretion thatproduces prolonged enhancement of liver parenchyma on T1-weighted images (1)(2)(3). The purpose of this study was to compare quantitatively [in terms of liver signal-to-noise ratio (SNR) and lesion-liver contrast-to-noise ratio (CNR)] the performance of spin-echo (SE) and gradient-recalled-echo (GRE) T1-weighted pulse sequences before and after administration of two different doses of Gd-BOPTA.…”

mentioning

confidence: 99%

MR imaging of the liver with Gd-BOPTA: Quantitative analysis of T1-weighted images at two different doses

Schima¹,

Saini²,

Petersein³

et al. 1999

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA)

Manfredi

Maresca

Baron

et al. 1999

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

The purpose of this study was to determine the efficacy of gadobenate dimeglumine (Gd‐BOPTA)‐enhanced magnetic resonance (MR) imaging for evaluation of hepatocellular carcinoma HCC. MR images were obtained in 14 patients with 31 HCC nodules as a part of a phase III clinical trial. T1‐ and T2‐weighted images were obtained before and after iv administration of 0.1 mmol/kg of Gd‐BOPTA. Two blinded readers evaluated pre‐ and delayed postcontrast images separately for detection of tumor nodules. Quantitative measurements of signal‐to‐noise (SNR) and tumor/liver contrast‐to‐noise (CNR) ratios were also performed. A signal/intensity ratio was calculated. Tumor enhancement was correlated with histologic findings. Consensus agreement of precontrast T1‐ and T2‐weighted images revealed 23/31 HCC nodules in 14 patients; postcontrast T1‐weighted images demonstrated 24/31 HCC nodules in the same number of patients. Combining both pre‐ and postcontrast images, 27/31 lesions were detected. Four patients had four well‐differentiated HCC nodules detected only on postcontrast images, while three well‐differentiated lesions in two patients were only seen on precontrast images. Quantitative evaluation showed an SNR ratio increase in both liver parenchyma and HCC nodules, as well as a significant increase in the absolute CNR ratio on postcontrast T1‐weighted gradient‐recalled images (P < 0.05). Well‐differentiated HCC lesions showed a greater enhancement than poorly differentiated HCC lesions. J. Magn. Reson. Imaging 1999;9:704–710. © 1999 Wiley‐Liss, Inc.

show abstract

Soluble‐type hepatobiliary contrast agents for MR imaging

Cited by 51 publications

References 23 publications

Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

MR imaging of the liver with Gd-BOPTA: Quantitative analysis of T1-weighted images at two different doses

Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA)

Contact Info

Product

Resources

About